Amyotrophic Lateral Sclerosis (ALS): Pharmacologic Insights, Clinical Management, and Exam Essentials

Every year, approximately 1 in 100,000 adults in the United States is diagnosed with amyotrophic lateral sclerosis (ALS), a relentlessly progressive neurodegenerative disease that destroys the motor neurons that control voluntary movement. Imagine a 52‑year‑old electrician who, after a routine check‑up, reports difficulty turning a doorknob. Within months, his speech is slurred, his hand tremors, and eventually he requires a ventilator. This clinical vignette underscores why ALS remains a critical learning point for pharmacists and clinicians alike: the disease’s rapid decline, the limited therapeutic arsenal, and the need for early, precise pharmacologic intervention.

Introduction and Background

ALS, also known as Lou Gehrig’s disease, was first described in 1869 by French neurologist Jean-Martin Charcot. Over the past five decades, research has illuminated a complex pathophysiology involving excitotoxicity, oxidative stress, mitochondrial dysfunction, protein aggregation, and neuroinflammation. The disease is clinically heterogeneous, with sporadic cases accounting for ~90–95% and familial ALS (fALS) for the remainder, often linked to pathogenic variants in genes such as SOD1, C9orf72, TARDBP, and FUS.

From a pharmacologic standpoint, the only FDA‑approved disease‑modifying agents are riluzole (1995) and edaravone (2017). Riluzole belongs to the class of glutamate antagonists, while edaravone is a free‑radical scavenger. Both aim to temper the cascade of neurodegeneration, albeit through distinct mechanisms. In addition, antisense oligonucleotide (ASO) therapies, most notably tofersen for SOD1‑positive ALS, represent a burgeoning class of precision drugs that promise to modify disease at the genetic level.

Mechanism of Action

Glutamatergic Modulation by Riluzole

Riluzole’s primary neuroprotective effect is the attenuation of excitotoxic glutamate release. At the presynaptic terminal, riluzole binds to voltage‑gated sodium channels, reducing the influx of Na⁺ and thereby limiting the depolarization that triggers glutamate exocytosis. Additionally, riluzole inhibits postsynaptic AMPA and NMDA receptor activity by decreasing receptor phosphorylation, which dampens calcium influx. The net result is a reduction in intracellular Ca²⁺ overload, a known driver of motor neuron apoptosis. Riluzole’s modest effect on glutamate transporters (GLT‑1) also contributes to lower extracellular glutamate concentrations, further protecting vulnerable neurons.

Free‑Radical Scavenging by Edaravone

Edaravone is a potent, lipophilic free‑radical scavenger that neutralizes reactive oxygen species (ROS) such as hydroxyl radicals (•OH) and peroxyl radicals (ROO•). The drug undergoes rapid oxidation to a stable radical, which then donates an electron to the ROS, terminating chain reactions that would otherwise damage lipids, proteins, and DNA. By preserving mitochondrial integrity and preventing oxidative damage to axonal membranes, edaravone interrupts one of the key pathways of motor neuron degeneration. Importantly, edaravone does not affect glutamate signaling directly, allowing it to complement the pharmacologic action of riluzole when used concurrently.

Antisense Oligonucleotide Therapy: Tofersen

Tofersen is a second‑generation ASO designed to bind the mRNA of mutant SOD1, thereby promoting its degradation via RNase H‑dependent cleavage. This selective knockdown reduces the toxic gain‑of‑function protein product, lowering oxidative stress and aberrant protein aggregation. Tofersen is administered via intrathecal injection, ensuring direct delivery to the central nervous system and bypassing the blood‑brain barrier. Early phase trials have shown slowed functional decline in patients with SOD1 mutations, marking a paradigm shift toward genotype‑specific therapeutics in ALS.

Clinical Pharmacology

Riluzole is orally administered once daily, typically at 50 mg. Peak plasma concentration (Tmax) occurs 1–2 h post‑dose, with a mean half‑life of 12–14 h. The drug is extensively metabolized in the liver, primarily by CYP1A2, and is excreted 30–40 % as metabolites in urine and 60–70 % via feces. Riluzole’s bioavailability is ~50 % and is dose‑dependent. Edaravone is given as a 60‑minute intravenous infusion at 30 mg/m², repeated every 14 days for 6 weeks, followed by a 6‑week pause and then a 12‑week maintenance phase. Its half‑life is ~5 h, with renal excretion accounting for 80 % of the dose.

Therapeutic Applications

• Riluzole – FDA‑approved for all ALS patients; standard dose 50 mg BID or 100 mg QD, depending on weight and hepatic function.

• Edaravone – FDA‑approved for ALS patients with preserved respiratory function (FVC > 60 % predicted); dosing as described above.

• Tofersen – Investigational, approved in Japan for SOD1‑positive ALS; intrathecal 300 mg every 4 weeks.

• Combination Therapy – Emerging evidence suggests additive benefit of riluzole plus edaravone; clinical trials are ongoing.

• Off‑label/Experimental – Riluzole has been studied in frontotemporal dementia and spinal muscular atrophy, but evidence is inconclusive.

• Special Populations – Pediatric ALS is rare; dosing is weight‑based. Geriatric patients require monitoring for hepatic impairment. Renal impairment (<30 mL/min) necessitates dose adjustment for edaravone. Pregnancy category B for riluzole; limited data on edaravone.

Adverse Effects and Safety

Riluzole’s most common adverse effects include nausea (10–15 %), mild hepatotoxicity (elevated ALT/AST in 5–10 %), and rash (2–5 %). Rarely, it can cause severe hepatotoxicity requiring discontinuation. Edaravone’s side‑effect profile is dominated by infusion‑related reactions (fever, chills) and neutropenia (3–4 %). Serious adverse events include hypersensitivity reactions and, rarely, pulmonary embolism. Tofersen is associated with back pain at the injection site and transient elevations in liver enzymes.

Clinical Pearls for Practice

• Start Riluzole Early – The greatest benefit is seen when therapy begins within 6 months of symptom onset.

• Monitor Liver Function – Baseline ALT/AST and repeat every 4 weeks; discontinue if ALT > 3× ULN.

• Edaravone Requires Intact Respiratory Reserve – Only patients with FVC > 60 % predicted are eligible; reassess FVC every 3 months.

• Combination Therapy May Be Synergistic – Current trials suggest that riluzole plus edaravone slows functional decline more than either alone.

• Avoid CYP1A2 Inducers with Riluzole – Rifampin, carbamazepine, and smoking can lower riluzole plasma levels, reducing efficacy.

• Use the “RILUZE” Mnemonic – R‑Riluzole, I‑Initiate early, L‑Liver monitoring, U‑Use in combination, Z‑Zero tolerance for hepatotoxicity, E‑Evidence‑based dosing.

• Pregnancy Considerations – Riluzole is category B; no robust data for edaravone; counsel patients accordingly.

• Genotype‑Specific Therapy is the Future – Keep abreast of ASO developments for SOD1, C9orf72, and other mutations.

Comparison Table

Exam‑Focused Review

Students frequently encounter questions that test their grasp of ALS pharmacology. Typical stems include “Which drug is the only FDA‑approved disease‑modifying therapy for ALS?” or “What is the primary mechanism by which riluzole confers neuroprotection?” Another common format tests differential diagnosis: “A 45‑year‑old presents with progressive muscle weakness and dysarthria. Which drug should be initiated first?” Key differentiators to remember are: riluzole’s glutamate inhibition vs. edaravone’s oxidative‑stress reduction; the need for FVC > 60 % for edaravone; and the genotype‑specific nature of ASO therapies. For NAPLEX, be prepared to answer dosing questions (e.g., riluzole 50 mg BID vs. 100 mg QD) and monitoring schedules. USMLE Step 2 CK may test knowledge of adverse‑effect monitoring, such as LFT checks for riluzole and CBC for edaravone. Always recall the “RILUZE” mnemonic to anchor core facts.

Key Takeaways

1. ALS is a rapidly progressive motor neuron disease with limited disease‑modifying options.

2. Riluzole is the first‑line therapy, acting by inhibiting glutamate release.

3. Edaravone targets oxidative stress and is reserved for patients with adequate respiratory function.

4. ASO therapy (tofersen) is emerging for SOD1‑positive ALS and exemplifies genotype‑specific treatment.

5. Early initiation (within 6 months of onset) maximizes benefit for both riluzole and edaravone.

6. Routine monitoring of liver enzymes and complete blood counts is essential to detect drug toxicity.

7. Drug interactions, especially CYP1A2 inducers, can diminish riluzole efficacy.

8. Pregnancy data are limited; counsel patients on potential risks.

9. Combination therapy (riluzole + edaravone) shows promise but requires further validation.

10. Staying current on emerging therapies will be critical as ALS treatment evolves.

Always remember: in ALS, the window for therapeutic intervention closes quickly; early, evidence‑based pharmacologic management can meaningfully delay functional decline.